Viewing Study NCT04956692

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:30 PM
Ignite Modification Date: 2026-02-03 @ 4:52 PM
Study NCT ID: NCT04956692
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-12-03
First Post: 2021-07-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-Small Cell Lung Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death 1 (PD1, PD-1) View
None Programmed Cell Death-Ligand 1 (PDL1, PD-L1) View
None Programmed Cell Death-Ligand 2 (PDL2, PD-L2) View